Characterization of NPY receptors mediating contraction in rat intramyocardial coronary arteries

Regulatory Peptides

Volumn 75-76, Issue , 1998, Pages 155-160

  Prieto, Dolores ^a   García Sacristán, Albino ^a   Simonsen, Ulf ^b  

^a UNIVERSIDAD COMPLUTENSE DE MADRID   (Spain)

^b AARHUS UNIVERSITY   (Denmark)

Author keywords

BIBP 3226; Coronary artery; Neuropeptide Y; NPY receptor subtype; Prostanoids; Rat coronary artery

Indexed keywords

15 HYDROXY 11ALPHA,9ALPHA EPOXYMETHANOPROSTA 5,13 DIENOIC ACID; 7 [3 [(4 PHENYLSEMICARBAZIDO)METHYL] 7 OXABICYCLO[2.2.1]HEPT 2 YL] 5 HEPTENOIC ACID; INDOMETACIN; NALPHA (DIPHENYLACETYL) N (4 HYDROXYBENZYL) DEXTRO ARGININAMIDE; NEUROPEPTIDE Y; NEUROPEPTIDE Y DERIVATIVE; NEUROPEPTIDE Y RECEPTOR; NEUROPEPTIDE Y RECEPTOR AGONIST; NEUROPEPTIDE Y RECEPTOR ANTAGONIST; PEPTIDE YY; RECEPTOR SUBTYPE;

ANIMAL TISSUE; ARTERY CONSTRICTION; ARTICLE; CONTROLLED STUDY; CORONARY VASCULAR RESISTANCE; DOSE RESPONSE; ENDOTHELIUM; IN VITRO STUDY; MALE; MYOGRAPHY; NONHUMAN; PRIORITY JOURNAL; RAT;

ANIMALS; ARGININE; CORONARY VESSELS; HYDRAZINES; INDOMETHACIN; MALE; MUSCLE, SMOOTH, VASCULAR; NEUROPEPTIDE Y; PEPTIDE YY; PROSTAGLANDINS; RATS; RATS, WISTAR; RECEPTORS, NEUROPEPTIDE Y; RECEPTORS, THROMBOXANE; VASOCONSTRICTION;

EID: 0032566828     PISSN: 01670115     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0167-0115(98)00063-9     Document Type: Article

References (36)

1. Tatemoto K., Carlquist M., Mutt V. Neuropeptide Y: a novel brain peptide with structural similarities to peptide YY and pancreatic polypeptide. Nature. 296:1982;659-660.
2. Lundberg J.M. Pharmacology of cotransmission in the autonomic nervous system: integratives aspects on amines, neuropeptides, adenosin triphosphate, aminoacides and nitric oxide. Pharmacol. Rev. 48:1996;113-178.
3. Edvinsson L., Håkanson R., Wahlestedt C., Uddman R. Effects of neuropeptide Y on the cardiovascular system. TIPS. 8:1987;231-232.
4. Pernow J., Lundberg J.M. Modulation of noradrenaline and neuropeptide Y (NPY) release in the pig kidney in vivo: involvement of alpha2, NPY and angiotensin II receptors. Naunyn-Schmiedeberg's Arch. Pharmacol. 340:1989;379-385.
5. McAuley N.A., Westfall T.C. Possible location and function of neuropeptide Y receptor subtypes in the rat mesenteric arterial bed. J. Pharmacol. Exp. Ther. 261:1992;863-868.
6. Abel PW, Han C. Effects of neuropeptide Y on contraction, relaxation and membrane potential of rabbit cerebral arteries. J. Cardiovasc Pharmacol 1989;1352-63.
7. Prieto D., Buus C., Mulvany M.J., Nilsson H. Interactions between neuropeptide Y and the adenylate cyclase pathway in rat mesenteric small arteries: role of membrane potential. J. Physiol. 502(2):1997;281-292.
8. Larhammar D. Structural diversity of receptors for neuropeptide Y, peptide YY, and pancreatic polypeptide. Reg. Pept. 65:1996;165-174.
9. Michel M.C., Beck-Sickinger A., Cox H., Doods H., Herzog H., Larhammar D., Quirion R., Schwartz T., Westfall T. XVI International Union of Pharmacology Recommendations for the Nomenclature of Neuropeptide Y, Peptide YY and Pancreatic Polypeptide Receptors. Pharmacol. Rev. 50:1998;143-150.
10. Rudolf K., Eberlein W., Engel W., Wieland H.A., Willim K.D., Entzeroth M., Wienen W., Beck-Sickinger A.G., Doods H.N. The first highly potent and selective non-peptide neuropeptide Y Y1 receptor antagoninst: BIBP 3226. Eur. J. Pharmacol. 271:1994;R11-R13.
11. Doods H.N., Wieland F.A., Engel W., Eberlein W., Willim K.-D., Entzeroth M., Wienen W., Rudolf K. B1BP3226, the first selective neuropeptide Y1 receptor antagonist: A review of its pharmacological properties. Reg. Pept. 65:1996;71-77.
12. Clarke J.G., Davies G.J., Kerwin R., Hackett D., Larkin S., Dawbarn D., Lee Y., Bloom S.R., Yacoub M., Maseri A. Coronary artery infusion of neuropeptide Y in patients with angina pectoris. Lancet. 1:1987;1057-1059.
13. Maturi M.R., Greene R., Speir E., Burrus C., Dorsey L.M.A., Markle D.R., Maxwell M., Schmidt W., Goldstein S.R., Patterson R.E. Neuropeptide-Y. A peptide found in human coronary arteries constricts primarily small coronary arteries to produce myocardial ischaemia in dogs. J. Clin. Invest. 83:1989;1217-1224.
14. Franco-Cereceda A., Lundberg J.M. Potent effects of neuropeptide Y and calcitonin gene-related peptide on human coronary vascular tone in vitro. Acta Physiol. Scand. 131:1987;159-160.
15. Prieto D., Benedito S., Simonsen U., Nyborg N.C.B. Regional heterogeneity in the contractile and potentiating effects of neuropeptide Y in rat isolated coronary arteries: modulatory role of the endothelium. Br. J. Pharmacol. 102:1991;754-758.
16. Mulvany M.J., Nyborg N.C.B. An increased calcium sensitivity of mesenteric resistance vessels in young and adult spontanously hypertensive rats. Br. J. Pharmacol. 71:1980;585-596.
17. Arunlakshana O., Schild H.O. Some quantitative uses of drug antagonists. Br. J. Pharmacol. Chemother. 14:1959;48-58.
18. Grundemar L., Jonas S.E., Mörner N., Högestatt E.D., Wahlestedt C., Håkanson R. Characterization of vascular neuropeptide Y receptors. Br. J. Pharmacol. 105:1992;45-50.
19. Wahlestedt C., Reiss D.J. Neuropeptide Y-related peptides and their receptors are the receptors potential therapeutic drug targets? Ann. Rev. Pharmacol. Toxicol. 32:1993;306-352.
20. Gerald C., Walker M.W., Criscione L., Gustafson E.L., Batzl-Hartmann C., Smith K.B., Vayasse P., Durkin M.M., Laz T.M., Linemeyer D.L., Schaffhauser A.O. A receptor subtype involved in neuropeptide-Y-induced food intake. Nature. 382:1996;168-171.
21. Lundell I., Statnick M.A., Johnson D., Schober D.A., Starback P., Gehlert D.R., Larhammar D. The cloned rat pancreatic polypeptide receptor exhibits profound differences to the orthologous human receptor. Proc. Natl. Sci. USA. 93:1996;5111-5115.
22. 34-PYY is a high affinity radioligand for rat PPI/Y4 and Y1 receptors: evidence for heterogeneity in pancreatic polypeptide receptors. Peptides. 18:1997;397-401.
23. 2 receptor of neuropeptide Y. Eur. J. Pharmacol. 327:1997;163-167.
24. Prieto D., Hernández M., Rivera L., García-Sacristán A., Simonsen U. Distribution and functional effects of neuropeptide Y on equine ureteral smooth muscle and resistance arteries. Reg. Pept. 69:1997;155-165.
25. Tessel R.E., Miller D.W., Misse G.A., Dong X., Doughty M.B. Characterization of vascular postsynaptic NPY receptor function and regulation and differential sensitivity of Y1 and Y2 receptor function to changes in extracellular calcium availability and prior in vitro peptide exposure. Neuropeptides. 25:1993;289-298.
26. 1 receptor mechanisms in sympathetic vascular control. Acta Physiol. Scand. 636:1997;1-55.
27. Wieland H.A., Willim K.D., Entzeroth M., Wienen W., Rudolf K., Eberlein W., Engel W., Doods H.N. Subtype selectivity and antagonistic profile of the non-peptide Y 1 receptor antagonist BIBP 3226. J. Pharmacol. Exp. Ther. 275:1995;143-149.
28. Gehlert D.R., Schober D.A., Beavers L., Gadski R., Hoffman J.A., Smiley D.L., Chance R.E., Lundell I., Larhammar D. Characterization of the peptide binding requirements for the cloned human pancreatic polypeptide-preferring receptor. Mol. Pharmacol. 50:1996;112-118.
29. 1 antagonist B1BP3226. Br. J. Pharmacol. 116:1995;2245-2250.
30. Malström R.E., Lundberg J.M. Neuropeptide Y accounts for sympathetic vasoconstriction in guinea-pig vena cava: evidence using BIBP 3226 and 3435. Eur. J. Pharmacol. 294:1995;661-668.
31. 1-selective antagonist, BIBP 3226. Br. J. Pharmacol. 199:1996;1313-1318.
32. Michel M.C. Receptors for neuropeptide Y: multiple subtypes and multiple second messengers. TIPS. 12:1991;389-394.
33. Andriantsitohaina R., Bian K., Stoclet J.-C., Bukoski R.D. Neuropeptide Y increases force development through a mechanism that involves calcium entry in resistance arteries. J. Vascul. Res. 30:1993;309-314.
34. Prieto D., Simonsen U., Nyborg N.C.B. Reginal involvement of an endothelium-derived contractile factor in the vasoactive actions of neuropeptide Y in bovine isolated retinal arteries. Br. J. Pharmacol. 116:1995;2729-2737.
35. Lew M.J., Murphy R., Angus J.A. Synthesis and characterization of a selective peptide antagonist of neuropeptide Y vascular postsynaptic receptors. Br. J. Pharmacol. 117:1996;1768-1772.
36. 2. Am. J. Physiol. 263:1992;H1045-H1053.